Vaxxinity Inc
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial … Read more
Market Cap & Net Worth: Vaxxinity Inc (VAXX)
Vaxxinity Inc (PINK:VAXX) has a market capitalization of $5.65 Million ($5.65 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #35499 globally and #11565 in its home market, demonstrating a 24900.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vaxxinity Inc's stock price $0.05 by its total outstanding shares 112910552 (112.91 Million).
Vaxxinity Inc Market Cap History: 2021 to 2025
Vaxxinity Inc's market capitalization history from 2021 to 2025. Data shows change from $633.43 Million to $5.65 Million (-81.90% CAGR).
Vaxxinity Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vaxxinity Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
-158074.77x
Vaxxinity Inc's market cap is -158074.77 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $633.43 Million | $66.00K | -$137.18 Million | 9597.40x | N/A |
| 2022 | $158.07 Million | $-1.00K | -$75.21 Million | -158074.77x | N/A |
Competitor Companies of VAXX by Market Capitalization
Companies near Vaxxinity Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Vaxxinity Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Vaxxinity Inc Historical Marketcap From 2021 to 2025
Between 2021 and today, Vaxxinity Inc's market cap moved from $633.43 Million to $ 5.65 Million, with a yearly change of -81.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $5.65 Million | +49900.00% |
| 2024 | $11.29K | -99.99% |
| 2023 | $95.97 Million | -39.29% |
| 2022 | $158.07 Million | -75.04% |
| 2021 | $633.43 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Vaxxinity Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.65 Million USD |
| MoneyControl | $5.65 Million USD |
| MarketWatch | $5.65 Million USD |
| marketcap.company | $5.65 Million USD |
| Reuters | $5.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.